This photo taken in January 2024 shows an intelligent workshop of rice-derived recombinant human serum albumin of Healthgen ...

SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, ...

These platforms are enabling us to generate immediate revenue through high-value alternative protein applications including recombinant human albumin, transferrin, DNASE-1, and alpha-lactalbumin.

Q4 2024 Earnings Call Transcript March 26, 2025 Dyadic International, Inc. misses on earnings expectations. Reported EPS is $-0.05 EPS, expectations were $-0.04. Operator: Good evening. And welcome to ...

A Wuhan-based biopharmaceutical company developed technology to synthesize human serum albumin (HSA) from rice, offering a potential solution to China's supply shortage of this critical blood protein.

the Company’s proprietary version of recombinant human interleukin-12 (rhIL-12) configured using genetic fusion to Sonnet's Fully Human Albumin Binding (F H AB ®) platform, in combination with ...

The commercialization of some products, such as recombinant human serum albumin, is still pending and expected in 2025, indicating potential delays. The company faces regulatory hurdles in the ...

Sonnet BioTherapeutics (SONN) announced positive findings from the first safety review of the expansion cohort in its Phase 1 SB101 clinical ...

Karnataka: Shilpa Medicare has announced that the Company's marketing partner, Amneal Pharmaceuticals, has launched BORUZU, ...

Sonnet BioTherapeutics (SONN) announced safety results of SON-1010 at the highest dose combined with atezolizumab in the Phase 1b/2a clinical ...